CELGZ - Celgene Corporation - Contingen

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
1.60
+0.04 (+2.56%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close1.56
Open1.57
Bid0.00 x 900
Ask0.00 x 1000
Day's Range1.57 - 1.60
52 Week Range0.11 - 2.65
Volume9,327
Avg. Volume61,326
Market CapN/A
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Celgene sues pharma with Durham ops
    American City Business Journals3 months ago

    Celgene sues pharma with Durham ops

    Summit, New Jersey-based Celgene (Nasdaq: CELG) has filed a patent infringement lawsuit against Synthon over generic versions of Celgene’s valuable multiple myeloma drug products. While patent infringement suits against generic companies have remained common, the U.S. Food and Drug Administration has made recent statements about encouraging competition through timely market entry of generics.  The lawsuit – filed in the U.S. District Court for the Middle District of North Carolina – names Synthon Pharmaceuticals, Synthon B.V., Synthon C.R.O. and Alvogen Pine Brook as defendants in the case.

  • We're sorry this is all we were able to find about this topic.